Is Haemonetics Stock a Good Investment?
Haemonetics Investment Advice | HAE |
- Examine Haemonetics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Haemonetics' leadership team and their track record. Good management can help Haemonetics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Equipment & Supplies space and any emerging trends that could impact Haemonetics' business and its evolving consumer preferences.
- Compare Haemonetics' performance and market position to its competitors. Analyze how Haemonetics is positioned in terms of product offerings, innovation, and market share.
- Check if Haemonetics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Haemonetics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Haemonetics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Haemonetics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Small | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Haemonetics Stock
Researching Haemonetics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The book value of Haemonetics was currently reported as 17.44. The company has Price/Earnings To Growth (PEG) ratio of 1.11. Haemonetics had not issued any dividends in recent years. The entity had 2:1 split on the 3rd of December 2012.
To determine if Haemonetics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Haemonetics' research are outlined below:
| Haemonetics generated a negative expected return over the last 90 days | |
| Haemonetics is unlikely to experience financial distress in the next 2 years | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 161 shares by Roy Galvin of Haemonetics at 71.48 subject to Rule 16b-3 |
Haemonetics Quarterly Liabilities And Stockholders Equity |
|
Haemonetics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Haemonetics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Haemonetics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 8th of February 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 9th of May 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of March 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Haemonetics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Haemonetics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2003-07-24 | 2003-06-30 | 0.1 | 0.11 | 0.01 | 10 | ||
1999-10-28 | 1999-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
1999-01-29 | 1998-12-31 | 0.1 | 0.09 | -0.01 | 10 | ||
2004-07-29 | 2004-06-30 | 0.17 | 0.19 | 0.02 | 11 | ||
2004-05-03 | 2004-03-31 | 0.17 | 0.19 | 0.02 | 11 | ||
2004-01-22 | 2003-12-31 | 0.17 | 0.19 | 0.02 | 11 | ||
2003-10-23 | 2003-09-30 | 0.13 | 0.15 | 0.02 | 15 | ||
2001-01-25 | 2000-12-31 | 0.15 | 0.17 | 0.02 | 13 |
Haemonetics Target Price Consensus
Haemonetics target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Haemonetics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 10 | Strong Buy |
Most Haemonetics analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Haemonetics stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Haemonetics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationHaemonetics Target Price Projection
Haemonetics' current and average target prices are 69.47 and 110.80, respectively. The current price of Haemonetics is the price at which Haemonetics is currently trading. On the other hand, Haemonetics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Haemonetics Market Quote on 30th of January 2025
Target Price
Analyst Consensus On Haemonetics Target Price
Haemonetics Analyst Ratings
Haemonetics' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Haemonetics stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Haemonetics' financials, market performance, and future outlook by experienced professionals. Haemonetics' historical ratings below, therefore, can serve as a valuable tool for investors.Know Haemonetics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Haemonetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Haemonetics backward and forwards among themselves. Haemonetics' institutional investor refers to the entity that pools money to purchase Haemonetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Schroder Investment Management Group | 2024-09-30 | 937.3 K | Royal Bank Of Canada | 2024-09-30 | 928.1 K | Btim Corp | 2024-12-31 | 915.7 K | Westfield Capital Management Company, L.p. | 2024-09-30 | 823.7 K | Allspring Global Investments Holdings, Llc | 2024-09-30 | 795.4 K | Fmr Inc | 2024-09-30 | 774.5 K | Fisher Asset Management, Llc | 2024-09-30 | 689.5 K | Franklin Resources Inc | 2024-09-30 | 682 K | Sg Capital Management, Llc | 2024-09-30 | 643.4 K | Blackrock Inc | 2024-09-30 | 6.2 M | Vanguard Group Inc | 2024-09-30 | 5.2 M |
Haemonetics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.43 B.Market Cap |
|
Haemonetics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.05 | 0.08 | |
| Return On Capital Employed | 0.07 | 0.06 | |
| Return On Assets | 0.04 | 0.07 | |
| Return On Equity | 0.06 | 0.10 |
Determining Haemonetics' profitability involves analyzing its financial statements and using various financial metrics to determine if Haemonetics is a good buy. For example, gross profit margin measures Haemonetics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Haemonetics' profitability and make more informed investment decisions.
Haemonetics' Earnings Breakdown by Geography
Please note, the presentation of Haemonetics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Haemonetics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Haemonetics' management manipulating its earnings.
Evaluate Haemonetics' management efficiency
Haemonetics has Return on Asset of 0.0588 % which means that on every $100 spent on assets, it made $0.0588 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.1397 %, implying that it generated $0.1397 on every 100 dollars invested. Haemonetics' management efficiency ratios could be used to measure how well Haemonetics manages its routine affairs as well as how well it operates its assets and liabilities. At present, Haemonetics' Return On Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Equity is expected to grow to 0.10, whereas Return On Capital Employed is forecasted to decline to 0.06. At present, Haemonetics' Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 99.2 M, whereas Other Assets are forecasted to decline to 1.09.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 14.26 | 7.57 | |
| Tangible Book Value Per Share | 7.29 | 5.03 | |
| Enterprise Value Over EBITDA | 25.70 | 26.99 | |
| Price Book Value Ratio | 5.13 | 2.79 | |
| Enterprise Value Multiple | 25.70 | 26.99 | |
| Price Fair Value | 5.13 | 2.79 | |
| Enterprise Value | 1.4 B | 1.5 B |
Evaluating the management effectiveness of Haemonetics allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Haemonetics Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Beta 0.321 |
Basic technical analysis of Haemonetics Stock
As of the 30th of January, Haemonetics retains the Market Risk Adjusted Performance of (0.22), risk adjusted performance of (0.02), and Standard Deviation of 2.51. Haemonetics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Please check out Haemonetics standard deviation, maximum drawdown, kurtosis, as well as the relationship between the information ratio and potential upside to decide if Haemonetics is priced fairly, providing market reflects its last-minute price of 69.47 per share. Given that Haemonetics has information ratio of (0.06), we strongly advise you to confirm Haemonetics's regular market performance to make sure the company can sustain itself at a future point.Haemonetics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Haemonetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Haemonetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Haemonetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Haemonetics' Outstanding Corporate Bonds
Haemonetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Haemonetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Haemonetics bonds can be classified according to their maturity, which is the date when Haemonetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Understand Haemonetics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Haemonetics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 1.83 | |||
| Coefficient Of Variation | (3,293) | |||
| Standard Deviation | 2.51 | |||
| Variance | 6.32 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 16.85 | |||
| Value At Risk | (3.47) | |||
| Potential Upside | 3.57 | |||
| Skewness | 1.12 | |||
| Kurtosis | 4.24 |
| Risk Adjusted Performance | (0.02) | |||
| Market Risk Adjusted Performance | (0.22) | |||
| Mean Deviation | 1.83 | |||
| Coefficient Of Variation | (3,293) | |||
| Standard Deviation | 2.51 | |||
| Variance | 6.32 | |||
| Information Ratio | (0.06) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.31) | |||
| Treynor Ratio | (0.23) | |||
| Maximum Drawdown | 16.85 | |||
| Value At Risk | (3.47) | |||
| Potential Upside | 3.57 | |||
| Skewness | 1.12 | |||
| Kurtosis | 4.24 |
Consider Haemonetics' intraday indicators
Haemonetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Haemonetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 34735.66 | |||
| Daily Balance Of Power | 0.3907 | |||
| Rate Of Daily Change | 1.02 | |||
| Day Median Price | 69.49 | |||
| Day Typical Price | 69.48 | |||
| Price Action Indicator | 0.57 | |||
| Period Momentum Indicator | 1.18 |
Haemonetics Corporate Filings
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 12th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
F4 | 5th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Haemonetics Stock media impact
Far too much social signal, news, headlines, and media speculation about Haemonetics that are available to investors today. That information is available publicly through Haemonetics media outlets and privately through word of mouth or via Haemonetics internal channels. However, regardless of the origin, that massive amount of Haemonetics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Haemonetics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Haemonetics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Haemonetics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Haemonetics alpha.
Haemonetics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Haemonetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Haemonetics Historical Investor Sentiment
Investor biases related to Haemonetics' public news can be used to forecast risks associated with an investment in Haemonetics. The trend in average sentiment can be used to explain how an investor holding Haemonetics can time the market purely based on public headlines and social activities around Haemonetics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Haemonetics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Haemonetics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Haemonetics news discussions. The higher the estimate score, the more favorable the investor's outlook on Haemonetics.
Haemonetics Maximum Pain Price Across March 21st 2025 Option Contracts
Haemonetics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Haemonetics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Haemonetics' options.
Haemonetics Corporate Directors
| Robert Abernathy | Independent Director | Profile | |
| Claire Pomeroy | Independent Director | Profile | |
| Catherine Burzik | Independent Director | Profile | |
| Mark Kroll | Independent Director | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Haemonetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Haemonetics Stock refer to our How to Trade Haemonetics Stock guide.You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Haemonetics. If investors know Haemonetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Haemonetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.375 | Earnings Share 2.41 | Revenue Per Share | Quarterly Revenue Growth 0.086 | Return On Assets |
The market value of Haemonetics is measured differently than its book value, which is the value of Haemonetics that is recorded on the company's balance sheet. Investors also form their own opinion of Haemonetics' value that differs from its market value or its book value, called intrinsic value, which is Haemonetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Haemonetics' market value can be influenced by many factors that don't directly affect Haemonetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Haemonetics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Haemonetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Haemonetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.